COVID-19 vaccine Ad26.COV2.S

{
  "id": "MLC-T-ONC-012788",
  "term": "COVID-19 vaccine Ad26.COV2.S",
  "field": "Oncology and biomedicine",
  "definition": "A coronavirus vaccine composed of a genetically engineered, replication-incompetent, adenovirus serotype 26 (Ad26) vector expressing the stabilized pre-fusion spike (S) protein of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with potential immunomodulating and anti-COVID-19 activities. Upon intramuscular administration of the COVID-19 vaccine Ad26.COV2.S, the Ad26 infects human cells, which produces SARS-CoV-2 S protein. The released S protein activates the immune system to induce a humoral and cell-mediated immune response against SARS-CoV-2. This may prevent SARS-CoV-2 infection and inhibit viral replication. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.",
  "synonyms": [
    "Ad26-encoding SARS-CoV-2 spike protein vaccine",
    "Ad26.COV2.S",
    "Ad26COVS1",
    "Johnson and Johnson COVID-19 vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/covid-19-vaccine-ad26-cov2-s/"
}